Clinicopathologic Characteristics and Outcomes for Patients With G12D-Mutant NSCLC. PubMedĬooper AJ, Muzikansky A, Lennerz J, Narinesingh F, Mino-Kenudson M, Hung YP, Piotrowska Z, Dagogo-Jack I, Sequist LV, Gainor JF, Lin JJ, Heist RS. Selective Targeting of RET Fusions in Lung Cancer. Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies. PubMedĭagogo-Jack I, Abbattista A, Murphy JF, Krulewicz S, Do A, Peterson J, Lin JJ, Gainor JF, Messina R, Krueger EA, Thurm H, Yeap BY. High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities. Roh W, Geffen Y, Cha H, Miller M, Anand S, Kim J, Heiman DI, Gainor JF, Laird PW, Cherniack AD, Ock CY, Lee SH, Getz G.
Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2. Voutouri C, Hardin CC, Naranbhai V, Nikmaneshi MR, Khandekar MJ, Gainor JF, Stylianopoulos T, Munn LL, Jain RK. TGF-β in the microenvironment induces a physiologically occurring immune-suppressive senescent state. Matsuda S, Revandkar A, Dubash TD, Ravi A, Wittner BS, Lin M, Morris R, Burr R, Guo H, Seeger K, Szabolcs A, Che D, Nieman L, Getz GA, Ting DT, Lawrence MS, Gainor J, Haber DA, Maheswaran S.
These translational studies are complemented by a robust portfolio of phase I/II trials examining novel immunotherapy combinations
Our current research focus is to elucidate predictors of response and resistance to immune checkpoint inhibitors. My early efforts in this regard have focused on exploring the activity of immune checkpoint inhibitors among patients with oncogene-driven lung cancers. More recently, I have worked to transfer the same clinical-translational research framework pioneered in targeted therapies to the immunotherapy setting.
To complement these efforts, I have also led efforts to define the molecular mechanisms of resistance to targeted therapies. Currently, I am the principal investigator of multiple clinical trials evaluating novel targeted therapies among patients with oncogene-driven lung cancers, with a particular focus on oncogenic fusions involving anaplastic lymphoma kinase (ALK) and RET. My major research interests have centered around two themes: targeted therapy and immunotherapy. I am the Director of the Center for Thoracic Cancers at the Massachusetts General Hospital (MGH), Director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies, and Co-Leader of the SU2C Lung Cancer Dream Team.
0 kommentar(er)
